GlassScriptPhysician profile
Olga Cortez
NPI 1558479857
$20,422.17
in general payments reported to CMS, 2019-2025
37 companies · $7,308 in 2025
The $7,308 reported for 2025 was more than what 98% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,195 · 2020: $310 · 2021: $517 · 2022: $3,385 · 2023: $1,235 · 2024: $473 · 2025: $7,308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $6,000 · Food and Beverage: $1,332 · Consulting Fee: $1,000 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500 · Travel and Lodging: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $6,000.00 |
| Food and Beverage | $1,331.99 |
| Consulting Fee | $1,000.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
| Travel and Lodging | $183.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $17,018.99 | 2019-2025 | |
| Ibsa Pharma INC. | $1,173.82 | 2020-2025 | Tirosint, Tirosint, Licart |
| Abbvie INC. | $605.89 | 2019-2024 | Qulipta, Synthroid, Lo Loestrin Fe |
| Shield Therapeutics INC | $228.86 | 2024-2025 | |
| Lilly USA, LLC | $149.86 | 2021-2025 | Zepbound, Reyvow, Emgality |
| Antares Pharma, INC. | $146.74 | 2020-2024 | Xyosted |
| Pfizer INC. | $90.13 | 2023-2024 | |
| Novo Nordisk INC | $89.90 | 2019-2025 | Wegovy |
| Acella Pharmaceuticals, LLC | $80.05 | 2022-2025 | NP Thyroid 60 |
| Virtus Pharmaceuticals LLC | $64.77 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $56.80 | 2022 | |
| Organon LLC | $55.95 | 2021-2022 | |
| Sage Therapeutics, LLC | $52.45 | 2025 | Zurzuvae |
| Ironwood Pharmaceuticals, INC | $49.83 | 2019-2020 | |
| Therapeuticsmd, INC. | $44.87 | 2019-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $40.94 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $39.55 | 2025 | |
| Vivus LLC | $39.12 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $38.00 | 2021 | |
| Dexcom, INC. | $36.96 | 2025 | Dexcom G6 Transmitter |
| Hologic Sales and Service, LLC | $35.30 | 2022 | |
| Astellas Pharma US INC | $34.58 | 2024 | Veozah |
| Nalpropion Pharmaceuticals LLC | $25.77 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.74 | 2024 | Xifaxan, Trulance |
| Amgen INC. | $19.42 | 2020 | |
| Currax Pharmaceuticals LLC | $18.19 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $17.86 | 2025 | Qelbree |
| Endo Pharmaceuticals INC. | $17.67 | 2019 | |
| Daiichi Sankyo INC. | $17.38 | 2021 | |
| Exeltis, USA INC. | $16.02 | 2023 | Slynd |
| Scynexis, INC. | $15.09 | 2022 | |
| Shire North American Group INC | $14.50 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.83 | 2020 | |
| Bausch Health US, LLC | $13.53 | 2020 | |
| Baxter Healthcare | $12.24 | 2021 | |
| Eisai INC. | $12.02 | 2019 | |
| Merck Sharp & Dohme LLC | $11.55 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olga Cortez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.